Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promisingapproach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Biotechnology

Health Care

Pharmaceutical

Minoryx Therapeutics

Marc Martinell

Virginia García

Sílvia Pascual

Régis Le Mestre

Pilar Pizcueta

Montse Marti

Marta Torres Galtes

Maria Rovira Masramon

María Pascual

Laura Rodríguez-Pascau

Josep Roca-i-Camps

Hans Christian Keller

Damia Tormo

Cristina Vergara, PhD

Arun Mistry

Anna Vilalta

The Research and Development team at Minoryx Therapeutics is dedicated to discovering and developing innovative treatments for rare pediatric neurometabolic diseases of genetic origin. They focus on advancing small molecule drugs, particularly pharmacological chaperones, and explore drug repositioning strategies to rapidly bring effective therapies to patients. The team consists of R&D managers and senior scientists who drive these projects forward through rigorous scientific research and project management.

Research and Development

Clinical Operations

Leadership Team

Research and Development

About

Team members

Other teams at Minoryx Therapeutics

Clinical Operations

Leadership Team